[Efficacy and safety of induction chemotherapy consisting of anthracycline for 3 days and cytarabine for 7 days in elderly patients with acute myeloid leukemia].
Optimal therapeutic strategy for elderly patients with acute myeloid leukemia has not been established. We retrospectively reviewed the medical records of 24 patients who underwent induction chemotherapy, consisting of anthracycline for 3 days and cytarabine for 7 days. Regimens of induction therapy included cytarabine and daunorubicin (n=19), cytarabine and idarubicine (n=3), enocitabine and daunorubicin (n=2). Eleven patients (45.8%) achieved complete remission (CR). Three patients (12.5%) died without relapse or of progression underlying diseases. Of the 11 patients who achieved CR, 9 received consolidation therapy. The median survival was 11.2 months, and the median of event-free survival and overall survival in the patients who achieved CR was 9.4 months and 21.6 months, respectively. This study indicated that induction chemotherapy which consisted of anthracycline for 3 days and cytarabine for 7 days is effective and safe for elderly patients with acute myeloid leukemia.
Kurahashi
Shingo
S
Dept. of Hematology and Oncology, Toyohashi Municipal Hospital.
Iwasaki
Toshihiro
T
Suzuki
Hitoshi
H
Sawamoto
Akiyo
A
Sugimoto
Takumi
T
Narimatsu
Hiroto
H
Adachi
Tatsuya
T
Hayakawa
Fumihiko
F
Sugiura
Isamu
I
D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D012074:Remission Induction
D018943:Anthracyclines; D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine